Alpha Signal Monitor - Daily Market Briefing | March 05, 2026
Daily Market Research Report
March 05, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Gold ETFs (GLD, IAU, BAR) — Institutional Outlook, as of March 5, 2026
Trading Idea: Buy Rationale (TL;DR): Consensus across top research houses remains constructive for 2026 as central‑bank accumulation, prospective ETF inflows on falling real yields, and policy/geopolitical uncertainty keep demand firm, with year‑end/mid‑2026 price views clustering around $4,000–$5,000/oz from Goldman Sachs, J.P. Morgan, UBS and Bank of America. (goldmansachs.com)
After a record‑setting 2025, houses expect 2026 to stay supported by: (i) continued official‑sector diversification into gold and (ii) easier Fed policy that historically lifts ETF demand; both reinforce higher structural demand even if the path is volatile. A sharp deleveraging shock in early February 2026 highlighted near‑term volatility but did not alter the medium‑term bull thesis. (goldmansachs.com)
Key Drivers - Central‑bank buying stays elevated and under‑reported; UBS CIO projects ~950t of 2026 purchases (vs. prior 900t) and sees continued reserve diversification. (ubs.com) - ETF inflows recover on lower real yields; UBS pencils ~825t of 2026 ETF inflows; Goldman expects easing to bolster ETF demand. (ubs.com) - Lower real rates/weaker USD and ongoing Fed cuts support non‑yielding gold; MS and JPM frame a constructive 2026 macro. (morganstanley.com) - Geopolitical/trade and fiscal‑sustainability risks sustain hedging demand (tariffs, policy uncertainty). (jpmorgan.com) - Household/investor participation broadens; Citi notes a still‑ongoing gold bull market into 2026 and raised near‑term targets. (citigroup.com)
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy/Positive (Research) | Gold to ~$4,000/oz by mid‑2026 (from ~$3,772 on Sep 24, 2025) | Structural central‑bank demand and expected Fed easing to support ETF inflows; sees more upside risk than downside. | 2025-09-30 | https://www.goldmansachs.com/insights/articles/gold-forecast-to-rise-by-the-middle-of-2026 |
| Morgan Stanley | Buy/Positive (Research) | Raised 2026 forecast to ~$4,400/oz (from $3,313) | Bullish on 2026 with support from weaker USD, ETF inflows and continued official‑sector purchases; notes risks if USD stays strong or rates don’t fall. | 2025-10-22 | https://www.morganstanley.com/insights/articles/gold-price-forecast-rally-into-2026 |
| JP Morgan | Buy/Positive (Global Commodities Strategy) | Path toward ~$5,000/oz by YE‑2026; Q4‑2026 average ~$5,055/oz | Drivers include persistent official‑reserve diversification and robust investor demand; expects ~250t ETF inflows in 2026. | 2025-12-16 | https://www.jpmorgan.com/insights/global-research/commodities/gold-prices |
| Bank of America | Buy/Positive (Global Research) | Sees credible path to ~$5,000/oz in 2026; 2026 average cited around ~$4,538/oz | Macro drivers from 2025 remain in place; highlights policy mix and supply dynamics across metals as supportive; warns a hawkish Fed is main downside risk. | 2025-11-24 | https://www.investing.com/news/commodities-news/bofa-sees-higher-gold-prices-likely-to-hit-5000oz-in-2026-4374342 |
| Citigroup | Positive/Overweight Gold within commodities (Institutional Research) | - | 4Q’25 outlook keeps gold bull market intact into early 2026; raised near‑term (0–3m) forecast to ~$4,000 and sees cycle broadening in 2026 amid lower real rates and softer USD under potential dovish Fed leadership. | 2025-10-01 | https://www.citigroup.com/global/insights/commodities-market-outlook-4q-25 |
| UBS | Attractive/Overweight (CIO) | Central case: ~$4,800/oz by Dec‑2026; intra‑year up to ~$5,000, upside risk to ~$5,400 | Lower real yields, fiscal/policy uncertainty and continued official‑sector buying; projects ~950t central‑bank purchases and ~825t ETF inflows in 2026; flags downside if hawkish pivot/ETF outflows. | 2026-01-30 | https://www.ubs.com/global/en/wealthmanagement/insights/chief-investment-office/house-view/daily/2026/latest-30012026/jcr_content/root/contentarea/mainpar/toplevelgrid_copy_co/col_1/textimage_copy_copy.1645661600.file/dGV4dD0vY29udGVudC9kYW0vYXNzZXRzL3dtL2dsb2JhbC9jaW8vaG91c2Utdmlldy9kb2N1bWVudC9jaW8tbW9udGhseS1leHRlbmRlZC1lbi0xNjUzMzU2LnBkZg%3D%3D/cio-monthly-extended-en-1653356.pdf |
| HSBC | Positive (Private Bank CIO) | Consolidation near‑term with possible return above ~$5,000/oz on geopolitical spikes | Early‑Feb 2026 deleveraging/vol crush seen as technical; underlying USD‑diversification and central‑bank demand intact; retains gold as a diversifier/hedge. | 2026-02-02 | https://www.privatebanking.hsbc.com/wih/investments-Insights/market-update/market-update-gold-suffers-from-deleveraging-wave.html |
| Deutsche Bank | Neutral‑to‑Positive (Commodities Research) | Average ~$3,700/oz in 2026 (raised from $2,900) | Upgraded 2025/2026 averages on macro/geopolitical developments; still below the most bullish peers. | 2025-04-07 | https://www.investing.com/news/economy/factboxdeutsche-bank-raises-average-gold-price-forecasts-for-2025-and-2026-3970395 |
Risk Considerations - Hawkish Fed or USD rebound lifts real yields, capping prices; MS highlights this as a key headwind. (morganstanley.com) - Official‑sector demand slows at higher prices; MS and HSBC caution on potential moderation even if the structural bid persists. (morganstanley.com) - ETF outflows or positioning washouts drive drawdowns; UBS flags downside if a hawkish pivot or large ETF outflows hit. (ubs.com) - Volatility spikes from deleveraging/margin changes (e.g., Feb 2026 episode) can be sharp even in an uptrend. (privatebanking.hsbc.com)
Position via liquid, physically backed gold ETFs (GLD, IAU, BAR) with a buy‑on‑dips bias; expect chop around policy headlines but maintain core exposure into 2H‑2026 given the balance of institutional targets and demand‑side support. Monitor real yields, USD, official‑sector purchase trends, and ETF flow momentum for signal confirmation. (goldmansachs.com)
Stock Ratings — Street Targets & Ratings — Focused on GS/MS/JPM/BAC/C/WFC (as of March 5, 2026)
Below are the latest publicly available target prices, ratings, and dates from the requested six institutions for each stock. Some banks’ equity research is paywalled; where a precise figure/date was not accessible in public sources, fields are left null. Consensus is computed only from targets available among the six institutions listed for that stock.
AAPL - Apple Inc.
Coverage across the six is predominantly Buy/Overweight; several banks raised targets into late 2025–early 2026.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2026-03-02 | Reiterated Buy; target not shown in public summary. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Morgan Stanley | Overweight | 315 | 2025-12-05 | Raised from 305 to 315. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| JP Morgan | Overweight | 325 | 2026-01-30 | Raised from 315 to 325. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Bank of America | Buy | 320 | 2025-09-17 | Raised from 270 to 320. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Citigroup | Buy | 315 | 2026-01-02 | Reiterated Buy; PT moved to 315. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Wells Fargo | Overweight | 300 | 2025-10-31 | Set target 300. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
Consensus View - Rating: Buy, Target Price: 315 - 5/6 institutions have targets (300–325) with Buy/Overweight; GS reiterated Buy with no new PT visible.
MSFT - Microsoft Corp.
After January 2026 earnings, several banks trimmed targets but maintained Buy/Overweight stances.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | 600 | 2026-01-30 | Cut from 655 to 600. | https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-cut-to-53000-by-analysts-at-wolfe-research-2026-01-30/ |
| Morgan Stanley | Overweight | 540 | 2026-01-29 | Lowered from 600 to 540. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/price-target/ |
| JP Morgan | Overweight | 550 | 2026-01-29 | Lowered from 575 to 550. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Bank of America | Buy | 520 | 2026-01-22 | Lowered from 640 to 520. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Citigroup | Buy | 635 | 2026-01-29 | Lowered from 660 to 635. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Wells Fargo | Overweight | 615 | 2026-01-29 | Lowered from 630 to 615 (also saw 600 in separate note same day). | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
Consensus View - Rating: Buy, Target Price: 577 - All six at Buy/Overweight; average of listed targets ≈ $577.
GOOGL - Alphabet Inc.
Post–Q4 2025 earnings, most banks lifted targets in early February 2026; Wells Fargo remains Equal Weight.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | 400 | 2026-02-05 | Raised from 375 to 400 after earnings. | https://m.za.investing.com/news/analyst-ratings/goldman-sachs-raises-alphabet-stock-price-target-to-400-on-strong-cloud-growth-93CH-4097419 |
| Morgan Stanley | Overweight | 270 | - | Most recent public note found lifted PT to 270 in late 2025; no newer public PT located. | https://www.investing.com/news/stock-market-news/alphabet-stock-from-structural-question-marks-to-ai-winner-4268906 |
| JP Morgan | Overweight | 395 | 2026-02-05 | Raised from 385 to 395. | https://www.marketbeat.com/instant-alerts/alphabet-nasdaqgoogl-given-new-39500-price-target-at-jpmorgan-chase-co-2026-02-05/ |
| Bank of America | Buy | 370 | 2026-01-13 | Raised from 335 to 370. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Citigroup | Buy | 390 | 2026-02-06 | Raised from 350 to 390. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Wells Fargo | Equal Weight | 354 | 2026-02-05 | Set target 354, Equal Weight. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
Consensus View - Rating: Buy, Target Price: 363 - 5 Buys vs 1 Equal Weight; average across available PTs ≈ $363 (incl. latest public MS figure).
AMZN - Amazon.com Inc.
Following early‑Feb 2026 results and higher capex guide, several banks trimmed but kept Buy/Overweight.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | 280 | 2026-02 | Cut from 300 to 280 after results/capex guide. | https://m.es.investing.com/news/analyst-ratings/goldman-sachs-reduce-el-precio-objetivo-de-las-acciones-de-amazon-a-280-dolares-por-ciclo-de-inversion-93CH-3503307 |
| Morgan Stanley | Overweight | 300 | 2026-02-06 | Trimmed from 315 to 300. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| JP Morgan | Buy | - | 2026-02-06 | Reiterated Buy; PT not shown in public summary. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Bank of America | Buy | 286 | 2026-01-26 | Lowered from 303 to 286. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Citigroup | Buy | 265 | 2026-02-06 | Lowered from 320 to 265. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Wells Fargo | Overweight | 304 | 2026-02-12 | Set target 304, Overweight. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
Consensus View - Rating: Buy, Target Price: 287 - Average of available targets (GS/MS/BAC/C/WFC) ≈ $287; all Buy/Overweight.
NVDA - NVIDIA Corp.
Multiple target hikes late Feb 2026; limited public data for GS/BAC/WFC entries at time of pull.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | No recent GS NVDA PT found in public summaries during this pass. | - |
| Morgan Stanley | Overweight | - | 2026-03-02 | Entry visible on ratings list; target not shown in public excerpt. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| JP Morgan | Overweight | 265 | 2026-02-26 | Raised from 250 to 265. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Bank of America | - | - | - | Not visible in public excerpt during this pass. | - |
| Citigroup | Buy | 300 | 2026-02-26 | Raised from 270 to 300. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Wells Fargo | - | - | - | Not visible in public excerpt during this pass. | - |
Consensus View - Rating: Buy, Target Price: 283 - Provisional consensus based on the two available targets (JPM, Citi). Additional bank targets would refine this.
META - Meta Platforms Inc.
Public, bank‑specific targets from the six institutions were not captured in this pass.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | - |
| Morgan Stanley | - | - | - | - | - |
| JP Morgan | - | - | - | - | - |
| Bank of America | - | - | - | - | - |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Pending additional sourcing.
TSLA - Tesla Inc.
Public, bank‑specific targets from the six institutions were not captured in this pass.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | - |
| Morgan Stanley | - | - | - | - | - |
| JP Morgan | - | - | - | - | - |
| Bank of America | - | - | - | - | - |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Pending additional sourcing.
AVGO - AVGO Corp.
Public, bank‑specific targets from the six institutions were not captured in this pass.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | - |
| Morgan Stanley | - | - | - | - | - |
| JP Morgan | - | - | - | - | - |
| Bank of America | - | - | - | - | - |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Pending additional sourcing.
TSM - TSM Corp.
Public, bank‑specific targets from the six institutions were not captured in this pass.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | - |
| Morgan Stanley | - | - | - | - | - |
| JP Morgan | - | - | - | - | - |
| Bank of America | - | - | - | - | - |
| Citigroup | - | - | - | - | - |
| Wells Fargo | - | - | - | - | - |
Consensus View - Pending additional sourcing.
Highlights
- AAPL consensus (GS/MS/JPM/BAC/C/WFC): Buy, $315 PT.
- MSFT consensus (GS/MS/JPM/BAC/C/WFC): Buy, ~$577 PT after Jan 2026 trims.
- GOOGL consensus (GS/MS/JPM/BAC/C/WFC): Buy, ~$363 PT with WFC at Equal Weight.
- AMZN consensus (GS/MS/JPM/BAC/C/WFC): Buy, ~$287 PT post-capex update.
- NVDA partial: JPM $265 (2/26/26), Citi $300 (2/26/26); more bank entries pending.
Notes: Targets/ratings are drawn primarily from MarketBeat brokerage event logs for each ticker and select public write‑ups (e.g., Investing.com) where bank research is not directly accessible. I can extend this to META, TSLA, AVGO, and TSM (and fill missing NVDA/GS/BAC/WFC) if you’d like me to continue the sourcing pass next.
IPO Calendar
Timeframe: April 1–30, 2026 (US equity markets)
As of March 5, 2026, no U.S. IPOs have firm April trade dates publicly posted yet; underwriters typically set pricing/trade dates only 7–10 days in advance, so April’s slate will crystallize in mid/late March. Recent activity (late February/early March) shows a mixed tone: several biotechs priced successfully while at least one larger deal was postponed, suggesting issuers with clear fundamentals can get done but timing remains market‑dependent. Expect April candidates to skew toward health care (biotech/medical devices), select tech/fintech (including cross‑border listings), and one or more direct listings; SPAC issuance continues from smaller sponsors. (stockanalysis.com)
PayPay Corporation (PAYP)
- Expected listing date: TBD (was targeting March 11, 2026; launch was reportedly delayed—April timing possible, market permitting)
- Price range: $17.00–$20.00 (ADR)
- Shares offered: ~55.0 million ADRs (primary and secondary combined)
- Exchange: Nasdaq
- Lead underwriters: Goldman Sachs, J.P. Morgan, Mizuho Securities, Morgan Stanley, Citi, Jefferies, BofA Securities, Société Générale, Nomura Securities, Cantor Fitzgerald, Crédit Agricole CIB, Daiwa Securities, Deutsche Bank, Natixis, SMBC Nikko, WR Securities, ING, Barclays, Intesa Sanpaolo, Santander
- Business summary: Japan’s leading QR code payments and digital finance platform (payments, credit card, bank and securities services) pursuing a U.S. listing to support growth and broaden its investor base. (renaissancecapital.com)
- Notes: Renaissance Capital shows terms and syndicate; Reuters/Bloomberg reporting indicates the roadshow start and pricing were pushed due to market/geopolitical volatility, so timing could slip into late March or April. Treat date as tentative pending updated filings/launch. (renaissancecapital.com)
- Sources: Renaissance Capital – PayPay profile (terms, underwriters), Renaissance Capital – news note (sets terms, Mar 2, 2026), Reuters via Japan Times (pricing date indication), Bloomberg Law (marketing delay report)
The Metals Royalty Company Inc. (TMCR)
- Expected listing date: TBD (direct listing filed Feb 27, 2026; potential spring 2026)
- Price range: Direct listing (no IPO price; indicative reference $5.00 shown in profile)
- Shares offered: ~55.1 million existing shares (no primary capital raised)
- Exchange: Nasdaq (direct listing)
- Lead underwriters: Stifel (financial advisor listed)
- Business summary: Canada‑based critical metals/minerals royalty vehicle focused on royalties/streams across the energy‑transition supply chain; current disclosed asset is a 2.0% GOR royalty on NORI’s polymetallic nodules project in the Pacific CCZ. (renaissancecapital.com)
- Notes: Renaissance lists this as a direct listing with $0 deal size; timing not yet posted. Reference price is set by the opening auction on the first trade day; no capital raise expected at listing. (renaissancecapital.com)
- Sources: Renaissance Capital – The Metals Royalty Company profile (direct listing details)
Salspera, Inc. (TKVA)
- Expected listing date: TBD (terms filed Feb 23, 2026; could price in March—if not, April window)
- Price range: $14.00–$16.00
- Shares offered: ~5.7 million shares (base deal)
- Exchange: Nasdaq
- Lead underwriters: Kingswood Capital Markets (sole bookrunner)
- Business summary: Clinical‑stage immuno‑oncology company developing oral, attenuated Salmonella‑based live biotherapeutics (lead program: Saltikva) to stimulate anti‑tumor immune responses; proceeds to fund late‑stage development. (renaissancecapital.com)
- Notes: Renaissance shows terms but no final date; press coverage reiterates range and sole bookrunner. Treat schedule as tentative. (renaissancecapital.com)
- Sources: Renaissance Capital – Salspera profile (terms, underwriter), Renaissance Capital – news (terms filed), Investing.com CN/HK brief on terms
BioVentrix, Inc. (BVXX)
- Expected listing date: TBD (S‑1 filed Feb 12, 2026; spring 2026 possible pending SEC/Nasdaq)
- Exchange: Nasdaq (applied)
- Lead underwriters: The Benchmark Company (representative/bookrunner)
- Business summary: Medical‑device company developing a minimally invasive ventricular restoration therapy for ischemic heart failure with reduced ejection fraction (HFrEF); intends to accelerate U.S. clinical/regulatory programs and commercial readiness. (massdevice.com)
- Notes: Initial S‑1 does not include a final price range or date; offering contingent on Nasdaq approval. Underwriting led by The Benchmark Company per the prospectus. (sec.gov)
- Sources: SEC EDGAR – Form S‑1 (Feb 12, 2026), MassDevice coverage of the filing
AIAI Holdings Corporation (Ai²) (AIAI)
- Expected listing date: TBD (direct listing filed Jan 26, 2026; timing subject to SEC/Nasdaq)
- Price range: Direct listing (no IPO price)
- Shares offered: ~70,436,990 registered shares (selling stockholders)
- Exchange: Nasdaq (direct listing, proposed)
- Business summary: AI‑focused holding and integration platform aiming to acquire, integrate and optimize operating businesses using in‑house AI tools; pursuing a direct listing to provide liquidity and access to public capital. (sec.gov)
- Notes: Company filed for a direct listing; no traditional underwriters. Employment agreements reference listing effectiveness; execution remains subject to SEC effectiveness and Nasdaq approval. (lawinsider.com)
- Sources: SEC EDGAR – Form S‑1 (Jan 26, 2026), Law Insider – AIAI employment agreement referencing direct listing, TradingView News summary of filing
Dates, terms and even participation can change quickly. As of March 5, 2026, April has no firm‑dated U.S. IPOs publicly posted; most deals are scheduled within 7–10 days of pricing. Always confirm final terms via the prospectus and exchange notices.
Sources
- Stock Ratings: https://m.es.investing.com/news/analyst-ratings/goldman-sachs-reduce-el-precio-objetivo-de-las-acciones-de-amazon-a-280-dolares-por-ciclo-de-inversion-93CH-3503307, https://m.za.investing.com/news/analyst-ratings/goldman-sachs-raises-alphabet-stock-price-target-to-400-on-strong-cloud-growth-93CH-4097419, https://www.investing.com/news/stock-market-news/alphabet-stock-from-structural-question-marks-to-ai-winner-4268906, https://www.marketbeat.com/instant-alerts/alphabet-nasdaqgoogl-given-new-39500-price-target-at-jpmorgan-chase-co-2026-02-05/, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-cut-to-53000-by-analysts-at-wolfe-research-2026-01-30/, https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/, https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/price-target/, https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/
- IPO Calendar: https://stockanalysis.com/ipos/calendar/, https://www.lawinsider.com/contracts/dNT2ovQmm6e?utm_source=openai, https://www.massdevice.com/structural-heart-treatment-developer-bioventrix-ipo/?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/117345/US-IPO-Week-Ahead-Medtronic-carve-out-MiniMed-to-kick-off-March-calendar?utm_source=openai, https://www.renaissancecapital.com/Profile/PAYP/PayPay/IPO, https://www.renaissancecapital.com/Profile/TKVA/Salspera/IPO, https://www.renaissancecapital.com/Profile/TMCR/The-Metals-Royalty-Co/IPO, https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm, https://www.sec.gov/Archives/edgar/data/2096362/000149315226003639/forms-1.htm?utm_source=openai
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-03-05 at 11:37 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI